0000950170-24-078782.txt : 20240628
0000950170-24-078782.hdr.sgml : 20240628
20240628074508
ACCESSION NUMBER: 0000950170-24-078782
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240626
FILED AS OF DATE: 20240628
DATE AS OF CHANGE: 20240628
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tatsis Ourania
CENTRAL INDEX KEY: 0001789815
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40489
FILM NUMBER: 241081438
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS, INC.
STREET 2: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verve Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 824800132
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: (978) 501-3026
MAIL ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
4
1
ownership.xml
4
X0508
4
2024-06-26
0001840574
Verve Therapeutics, Inc.
VERV
0001789815
Tatsis Ourania
C/O VERVE THERAPEUTICS, INC.
201 BROOKLINE AVENUE, SUITE 601
BOSTON
MA
02215
true
false
false
false
false
Stock Option (right to buy)
5.02
2024-06-26
4
A
false
267541
0
A
2034-06-25
Common Stock
267541
267541
D
This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date of the option is the grant date. The shares of common stock underlying the option are scheduled to vest in equal monthly installments through June 26, 2027, subject to the Reporting Person's continued service as a director.
/s/ Andrew Ashe, as Attorney-in-Fact for Ourania Tatsis
2024-06-28